The Israeli biotechnology firm hopes that a successful outcome of the study with Centre Léon-Bérard will raise its profile among oncologists.
Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.
Investigators developed a pooled method for simultaneously sequencing RNA in bulk sets of samples being profiled by high-throughput screening assays.
The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database to uncover relationships between genetic variation and human health outcomes.
Horizon CombinatoRx will be paid $750,000 for the five-month project.
NEW YORK (GenomeWeb) – The National Institutes of Health has awarded $17 million to fund 11 research groups seeking to develop 3-D human tissue chips that can be used to predict drug safety and effectiveness, NIH said today.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.